[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adults":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,47,75,103,130,153,177,200,229,257,289,314,341,382,411,442,462,481,508,535,565,586,610,644],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100415769","effect-of-nano-structured-alumina-coating-on-the-bond-strength-of-zirconia-resin-bonded-fixed-dental-prostheses-100415769",false,"NCT04693949","Effect of Nano-structured Alumina Coating on the Bond Strength of Zirconia Resin-bonded Fixed Dental Prostheses","Inclusion Criteria:\n\n1\\. Patients with missing central or lateral incisor\n\nExclusion Criteria:\n\n1. inadequate edentulous space for the pontic\n2. signs of bruxism\n3. abutment tooth with active periodontal or periapical disease\n4. inadequate enamel bonding surface of the abutment tooth\n5. inadequate interocclusal space for a retainer wing and a proximal connector\n6. pontic guidance\n7. physical or psychological disease likely to interfere with normal conduct of the study",true,"ALL",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to evaluate the clinical outcome of resin-bonded fixed dental prostheses (RBFDPs) pretreated with nanostructured alumina coating (NAC).\n\nThe study adopts a prospective, randomized, controlled, double-blind design contrasting the use of NAC to air-borne particle abrasion (APA) (control) as a surface pretreatment method of zirconia RBFDPs used for replacing missing central or lateral incisors. The primary outcome evaluated is the retention\u002Fsurvival of the zirconia RBFDPs pretreated with APA and NAC.",[25,26,27,28,29],"Missing Incisors","Zirconia Surface Pretreatment","Children","Adults","Debonding",[31,32,33],"Airborne particle abrasion","Nanostructured alumina coating","Resin-bonded fixed dental prostheses","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":38},"2018-01-03",{"date":42,"type":19},"2030-01-01",{"name":44,"class":45},"University of Ljubljana, Faculty of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100537603","pupillometric-evaluation-in-patients-declared-brain-dead---a-prospective-quality-control-study-100537603","NCT06279975","Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study","Investigative Neurological Study With Pupillometric Evaluation os a Clinical Tool in Patients Declared Brain Dead (INSPECT) - a Prospective Quality Control Study","INSPECT","Inclusion Criteria:\n\n* Suspected diagnosis of brain death\n* Brain death diagnostic procedures planned\n* Treated at the intensive care unit at the University Hospital Basel (USB)","18 Years",{"count":57,"type":19},50,"OBSERVATIONAL","The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination.",[61,28],"Brain Death",[63,61,64],"Pupillometry","Diagnosis","2026-06-15",{"date":67,"type":38},"2026-06-17",{"date":69,"type":38},"2023-12-18",{"date":71,"type":19},"2030-12",{"name":73,"class":45},"University Hospital, Basel, Switzerland",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":20,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100643180","a-theory-based-sleep-hygiene-education-for-insomnia-disorder-100643180","NCT07642479","A Theory-based Sleep Hygiene Education for Insomnia Disorder","A Theory-based Sleep Hygiene Education for Insomnia Disorder - A Non-inferiority Randomized Controlled Trial With Mixed-method Process Evaluation and Cost-effectiveness Analysis","Inclusion Criteria:\n\n* Hong Kong residents\n* Ethnic Chinese aged 18-65 years with the ability to communicate in Cantonese or Putonghua\n* Who fulfil the DSM-5 diagnostic criteria for insomnia disorder according to a validated diagnostic tool, the Brief Insomnia Questionnaire\n* Scored at least 10 points in the Insomnia Severity Index\n* Willing to give informed consent\n\nExclusion Criteria:\n\n* Any current diagnosis fulfilling the DSM-IV criteria of a major depressive disorder, generalized anxiety disorders, post-traumatic stress disorder, panic disorder, substance use disorders, or schizophrenia as screened using the Chinese version of the Structured Clinical Interview for DSM-IV\n* Other sleep disorders, including circadian rhythm disorder, narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)\u002Fperiodic leg movement disorder (PLMD) as determined based on cut-off scores (≥ 7 on narcolepsy; ≥ 8 on circadian rhythm disorder; ≥ 15 on OSA; ≥ 7 on RLS\u002FPLMD) using SLEEP-50. If in doubt, subjects will be referred to our team psychiatrist (KF Chung) for further assessment\n* Any current medical conditions or side-effects of medication that are contributing significantly to the subject's insomnia\n* Taking medications or currently participating in other psychotherapies for insomnia or other psychiatric disorders\n* Impaired cognitive functioning (\\\u003C22 points in HK-MoCA) or with difficulty in giving consent or understanding instructions\n* Pregnant\n* Shift work","65 Years",{"count":84,"type":19},264,[22],"Insomnia is a prevalent sleep disorder associated with numerous adverse health outcomes, including fatigue, irritability, and impaired daytime functioning. Despite the availability of effective pharmacological and psychological treatments, relatively few individuals with insomnia seek professional help, highlighting the need for accessible and acceptable non-pharmacological interventions. Sleep hygiene education (SHE) has the potential to address this gap due to its simplicity, low cost, and ease of self-administration. Building on our previously registered pilot-testing protocol, this study aims to examine the effectiveness of a theory-based SHE program integrated with behavior change techniques in a larger community population. Furthermore, it remains unclear whether theory-based SHE is inferior to gold-standard interventions such as cognitive behavioral therapy for insomnia (CBT-I) delivered via digital applications. Therefore, this study will also compare the effectiveness of theory-based SHE with a CBT-I app using a three-arm randomized controlled trial design.",[88,28],"Insomnia",[88,90,91,92,28],"Sleep hygiene education","A non-inferiority randomized controlled trial","CBT-I apps","NOT_YET_RECRUITING","2026-06-07",{"date":96,"type":38},"2026-06-11",{"date":98,"type":19},"2026-07-10",{"date":100,"type":19},"2028-06-30",{"name":102,"class":45},"The Hong Kong Polytechnic University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":20,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":46},"100622577","phase-1-study-of-lgw16-03-to-identify-nerves-100622577","NCT07385430","Study of LGW16-03 To Identify Nerves","Phase 1 Study of LGW16-03 To Identify Nerves","Inclusion Criteria (All of the following criteria must be met by study participants to be eligible for study enrollment):\n\n1. Scheduled and medically cleared for a standard of care, open-field (not endoscopic) surgical procedure wherein a major nerve will be exposed and visible to the imaging equipment.\n2. Participants must be willing and able to provide informed consent for participation in the study and adhere to all study procedures.\n3. Intact motor and sensory function in the nerve to be imaged, as determined by physical exam performed by the operating surgeon or clinician on the study team, including:\n\n   1. 5\u002F5 motor strength in relevant muscle groups.\n   2. Normal sensation on testing with a 5.07 Semmes-Weinstein filament or other valid testing method.\n   3. No documented history of neuropathy of any kind.\n4. Age ≥ 18 years old.\n5. Medical clearance for surgery provided by a supervising medical provider (surgeon or primary care provider).\n6. Adequate renal function defined as creatinine clearance ≥ 60mL\u002Fmin.\n7. Adequate liver function:\n\n   1. Total bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN in patients with Gilbert's disease)\n   2. ALT and AST ≤ 2.5 x ULN if no active liver involvement or ALT and AST ≤ 5 xULN with active liver involvement\n   3. Albumin ≥3 g\u002FdL\n8. Adequate hematologic and clotting function:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL\n   2. Platelet count ≥ 100 x 109\u002FL\n   3. Hemoglobin ≥ 8 g\u002FdL or ≥ 5.6 mmol\u002FL\n   4. International Normalized Ratio (INR) ≤ 1.5 x ULN\n9. No growth factor support, transfusions, or albumin administration within 14 days of first dose of study treatment\n10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n11. If of childbearing potential, must have a negative urine or serum pregnancy test and be using a medically acceptable form of contraception (e.g., hormonal birth control, intrauterine devices, double-barrier method) or abstinence.\n\nExclusion Criteria (Any of the following criteria would exclude a participant from study enrollment):\n\n1. Pregnant or breastfeeding persons who are not willing to stop breastfeeding. Due to the unknown safety profile of LGW16-03 in humans, and the potential for fetal or neonatal exposure through transplacental transfer or breast milk, breastfeeding is not allowed throughout the study and until at least 60 days after last dose.\n2. Nerve injury or dysfunction of any kind in the nerve to be imaged (e.g., diabetic neuropathy, multiple sclerosis, other neuropathy, traumatic nerve injury)\n3. Peripheral vascular disease requiring management a vascular surgeon.\n4. Prior surgery in the planned surgical region within the previous 365 days.\n5. Abnormal cardiac rhythm not controlled with medication, history of stroke, coronary events and\u002For heart failure within 1 year.\n6. Current evidence of renal or liver disease.\n7. History of fluorescein allergy.\n8. Direct administration of a local anesthetic agent in the region of the nerve to be imaged that could affect the motor or sensory function of the target nerve.\n9. Any other criteria deemed by the Principal Investigator that may prevent the participant from successfully completing the trial.",{"count":111,"type":19},38,[113],"PHASE1","The primary goal of this study is to determine the safety and tolerability of LGW16-03, a novel nerve-labeling fluorophore, in participants undergoing open-field orthopaedic surgery. Secondary goals include: 1) identifying the lowest dose without adverse events that provides peak florescence imaging contrast, and 2) characterizing the pharmacokinetics of LGW16-03.\n\nParticipants will receive a one-time intravenous infusion of the investigational drug (LGW16-03) prior to their planned surgery. Participants' vitals will be closely monitored and will have blood samples taken at regular intervals. Fluorescence images of their major nerve will be taken during surgery. Participants will have one study follow-up visit approximately 30 days after their surgery.",[28,116,117],"Open-field Surgery","Major Nerve",[119,120,121],"Surgery","Nerve","Fluorescence imaging","2026-05-28",{"date":124,"type":38},"2026-06-01",{"date":65,"type":19},{"date":127,"type":19},"2027-08-01",{"name":129,"class":45},"Eric R. Henderson",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":82,"enrollmentInfo":137,"targetDuration":4,"studyType":20,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":46},"100635947","a-theory-based-sleep-hygiene-education-for-insomnia-patients-100635947","NCT07559305","A Theory-based Sleep Hygiene Education for Insomnia Patients","Developing a Theory-based Sleep Hygiene Education Intervention for Insomnia Patients - A Mixed Method Study","Inclusion Criteria:\n\n* Hong Kong residents\n* Ethnic Chinese aged 18-65 years with the ability to communicate in Cantonese or Putonghua\n* Fulfilled the DSM-5 diagnostic criteria for insomnia disorder according to a validated diagnostic tool, the Brief Insomnia Questionnaire. The criteria included having difficulties falling asleep, staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 months\n* Scored at least 10 points in the Insomnia Severity Index (ISI)\n* Willing to give informed consent\n\nExclusion Criteria:\n\n* Any current diagnosis fulfilling the DSM-IV criteria of a major depressive disorder, generalized anxiety disorders, post-traumatic stress disorder, panic disorder, substance use disorders, or schizophrenia as screened using the Chinese version of the Structured Clinical Interview for DSM-IV\n* Other sleep disorders, including circadian rhythm disorder, narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)\u002Fperiodic leg movement disorder (PLMD) as determined based on cut-off scores (≥ 7 on narcolepsy; ≥ 8 on circadian rhythm disorder; ≥ 15 on OSA; ≥ 7 on RLS\u002FPLMD) using SLEEP-50. If in doubt, subjects will be referred to our team psychiatrist (KF Chung) for further assessment\n* Any current medical conditions or side-effects of medication that are contributing significantly to the subject's insomnia\n* Taking medications or currently participating in other psychotherapies for insomnia or other psychiatric disorders\n* Impaired cognitive functioning (\\\u003C22 points in HK-MoCA) or with difficulty in giving consent or understanding instructions\n* Pregnant\n* Shift work",{"count":138,"type":19},10,[22],"Insomnia is a prevalent sleep disorder associated with substantial negative health consequences, including fatigue, irritability, and impaired daytime functioning. Although effective pharmacological and psychological treatments exist, fewer than half of individuals with insomnia seek professional treatment, highlighting the need for accessible and acceptable non-pharmacological interventions. Sleep hygiene education (SHE) has the potential to address this gap due to its simplicity, low cost, and ease of self-administration. However, previous studies have often underestimated the efficacy of SHE by using it as a passive control condition rather than an active, structured intervention. To address this limitation, the proposed pilot study aims to evaluate the feasibility and effectiveness of a theory-based, structured SHE program integrated with behavior change techniques.",[88,28],[88,143,144,28],"Sleep Hygiene Education","Pilot Testing","2026-05-02",{"date":147,"type":38},"2026-05-07",{"date":149,"type":19},"2026-05-10",{"date":151,"type":19},"2026-07-31",{"name":102,"class":45},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":15,"sex":16,"minAge":82,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":20,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100635548","postural-control-in-adults-100635548","NCT07554118","Postural Control in Adults","Enhancing Postural Control in Older Adults by Increasing Somatosensory Contribution","Inclusion Criteria:\n\n1. age 65 and above\n2. able to walk continuously for at least 10 min without assistive device\n3. have normal or corrected-to-normal vision.\n\nExclusion Criteria:\n\n1. neurological conditions such as stroke, Parkinson's disease, multiple sclerosis, brain tumor that significantly affect balance task and walking\n2. known peripheral neuropathy that influence sensation\n3. known vestibular dysfunction\n4. known cognitive impairments\n5. self-reported pain or musculoskeletal conditions that will significantly affect balance task and walking.\n6. Drug use in the past 3 month.\n7. At-risk drinker -","80 Years",{"count":162,"type":19},30,[22],"The investigators propose a 2-week intervention involving adults over 65 years old. Participants will undergo dynamic balance training on an movable platform (stabilometer) with either restricted or full vision. The primary objective is to facilitate sensory re-weighting, hypothesizing that restricted vision training will increase somatosensory input utilization for postural control. Pre- and post-training assessments will measure postural control during gait initiation under a dual-task condition. The investigators hypothesize that the restricted vision group will demonstrate:\n\n1. Improved postural control, indicated by increased center of pressure displacement during gait initiation.\n2. Improved ability to utilize somatosensory input during a balance task.",[166,28,167],"Older","Older Adults, Balance","2026-04-20",{"date":170,"type":38},"2026-04-28",{"date":172,"type":38},"2026-01-30",{"date":174,"type":19},"2026-12",{"name":176,"class":45},"University of Oklahoma",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":20,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":46},"100631975","impact-of-metacalm-on-stress-of-healthy-people-with-acute-stress-100631975","NCT07507669","Impact of MetaCalm on Stress of Healthy People With Acute Stress","Evaluation of MetaCalm at Two Dose Levels in Healthy Adults With Acute Stress: An Open-Label, Non-Randomized Clinical Study","Inclusion Criteria:\n\n* Providing written informed consent\n* Males and females of at least 18 years old\n* Obtaining a reference score of ≥ 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)\n\nExclusion Criteria:\n\n* Being on anxiolytic and beta blocker treatment\n* Individuals who use illicit or recreational drugs\n* Having consumed adaptogen plants in one week prior to enrollment\n* Participating in another clinical trial\n* Patients diagnosed with cancer\n* Allergic to any of the ingredients in this product\n* Obtaining a reference score of less than 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)",{"count":185,"type":19},280,[22],"This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.",[28,189],"Acute Stress Reaction","2026-04-08",{"date":192,"type":38},"2026-04-13",{"date":194,"type":19},"2026-04-15",{"date":196,"type":19},"2026-08-31",{"name":198,"class":199},"Metagenics, Inc.","INDUSTRY",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":20,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":46},"100630030","comparative-effects-of-scooping-mobilization-and-dynamic-cupping-therapy-on-elbow-stiffness-100630030","NCT07482371","Comparative Effects of Scooping Mobilization and Dynamic Cupping Therapy on Elbow Stiffness","Comparative Effects of Scooping Mobilization and Dynamic Cupping on Elbow Range of Motion and Function in Children With Elbow Stiffness","Inclusion Criteria:\n\n* Children of age group 6-13\n* Children with diagnosis of post-fracture elbow stiffness.\n* Minimal immobilized period of 3 weeks\n* Children with age group of both genders\n\nExclusion Criteria:\n\n* Infection or tumers\n* Neurological impairment\n* Children with MSK disorders\n* Metabolic bone disease\n* Pathological fractures","6 Years","13 Years",{"count":210,"type":19},28,[22],"The current study is a randomized clinical trial, data is collected from Alqamar Hospital Shakarghar. The study includes 28 patients equally divided into two groups and randomly allocated. Inclusion criteria for the study will be children of age group 6-13, children with diagonosis of post fracture stiff elbow minimal immobilized period of 3 weeks. Patients with any neurological impairment, children with MSK disorders, Infection or tumors will be excluded from the study. Experimental Scooping mobilization group will receive scooping mobilization combined with electrotherapy for 2 minutes per session 5 days a week. Experimental dynamic cupping group will receive dynamic cupping therapy combined with electrotherapy for 10 minutes per session 5 days a week. Total intervention period will be of 4 weeks. Data collection will be done before and after the intervention. Tools used for data collection will be Goniometer and Quick DASH Questionnaire. Data will be analyzed through SPSS version 27.00.",[27,28],[215,216,217,218,219],"Scooping mobilization","Dynamic cupping","ROM","Pain","Function","2026-03-16",{"date":222,"type":38},"2026-03-19",{"date":224,"type":38},"2025-10-22",{"date":226,"type":19},"2026-06-16",{"name":228,"class":45},"Riphah International University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":20,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":46},"100604484","cycling-based-aerobic-exercise-intervention-for-individuals-with-chemotherapy-induced-peripheral-neuropathy-cipn-100604484","NCT07150117","Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)","Evaluating the Acceptability of a Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Study","CYCLE-CIPN","Inclusion Criteria:\n\n* 18 years or older\n* Cancer diagnosis stage I to III\n* CIPN: grade 1 (mild)\n* Receiving or have received chemotherapy treatment for cancer\n* Speak, read and understand English\n\nExclusion Criteria:\n\n* Medical conditions that cause additional neuropathy symptoms (i.e. diabetes)\n* Any uncontrolled medical conditions\n* Will undergo surgery or radiation therapy during the study period\n* Are already receiving an aerobic exercise training program\n* Are already participating in an exercise-based research study\n* Are unable to provide signed informed consent",{"count":162,"type":19},[22],"CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility (\"go\u002Fno-go\") of a future larger-scale trial.\n\nThe protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants.\n\nThe Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.",[241,28],"Cancer",[243,244,245,246,247],"peripheral neuropathy","chemotherapy","exercise","aerobic","cancer","2026-03-11",{"date":250,"type":38},"2026-03-12",{"date":252,"type":38},"2026-01-26",{"date":254,"type":19},"2027-06-30",{"name":256,"class":45},"University of Alberta",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":160,"enrollmentInfo":265,"targetDuration":4,"studyType":20,"phases":266,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":46},"100627197","high-phenolic-olive-oil-for-enhancing-metabolic-health-a-randomized-controlled-trial-in-patients-with-central-obesity-hope-100627197","NCT07445503","High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)","High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With Central Obesity","HOPE","Inclusion Criteria:\n\n* Adult men and women 18-80 years of age,\n* Overweight\u002Fobesity (body mass index \\> 25 or waist circumference \\>94 cm for males and \\>80 cm for females), and\n* The presence of at least one of the following metabolic abnormality: (1) triglyceride level ≥150 mg\u002FdL or HDL cholesterol ≤40 mg\u002FdL in men and ≤50 mg\u002FdL in women; (2) increased blood pressure ≥ 130\u002F85 mm Hg; (3) elevated fasting blood sugar ≥100 mg\u002FdL; (4) standardized drug treatment regimen, and\n* Provided signed informed consent for participation.\n\nExclusion Criteria:\n\n* Concomitant acute or chronic disease (e.g., infection, cancer, chronic heart failure, kidney disease, autoimmune diseases like rheumatoid arthritis, inflammatory bowel diseases, Hashimoto),\n* Untreated diabetes,\n* Women at pregnancy or lactation,\n* Individuals with psychiatric or mental disorder,\n* Any use of antioxidant-phytochemical rich supplement, anti-, pre- or probiotics pre-intervention,\n* Drug and\u002For alcohol abuse,\n* Those who did not consent or were unable to provide consent.",{"count":18,"type":19},[22],"Olive oil is a fundamental component of the Mediterranean diet and a major source of monounsaturated fatty acids with well-established cardioprotective properties. When rich in phenolic compounds-such as hydroxytyrosol, tyrosol, oleuropein, oleocanthal, oleacein, and ligstroside aglycone-it is considered a functional food with antioxidant, anti-inflammatory, cardioprotective, chemoprotective, and neuroprotective effects. According to EU Regulation 432\u002F2012, daily consumption of 20 g of extra virgin olive oil containing at least 5 mg of hydroxytyrosol and tyrosol derivatives (250 mg\u002Fkg) contributes to the protection of blood lipids from oxidative stress and qualifies for a health claim.\n\nOverweight\u002Fobesity, characterized by excessive fat accumulation, is strongly associated with non-communicable diseases, including cardiovascular disease, type 2 diabetes, hypertension, certain cancers, and neurodegenerative disorders. Chronic low-grade inflammation and oxidative stress are key mechanisms underlying obesity-related metabolic disorders. Although dietary energy restriction remains the primary approach for weight management, growing research interest focuses on natural products rich in phenolic compounds as potential modulators of molecular pathways involved in central obesity.\n\nHowever, robust clinical evidence in humans with central obesity and metabolic abnormalities remains limited. Therefore, this double-blind, randomized, controlled trial aims to investigate the effects of extra virgin, high-phenolic olive oil (HPOO) compared with low-phenolic olive oil (LPOO) in adults with overweight\u002Fobesity with metabolic abnormalities. Participants will consume the assigned olive oil type (HPOO or LPOO) for eight weeks.\n\nAt baseline and trial endpoint (8 weeks), data collection will include anthropometric measurements, dietary intake, biochemical indices, inflammatory and oxidative stress markers in blood samples, hormones, bioavailability of phenolic compounds, as well as lifestyle parameters i.e., health-related quality of life, physical activity levels, sleep quality. Ethical approval, informed consent, and data protection procedures will be strictly followed. Statistical analyses will be conducted using SPSS software (SPSS Inc, ΙΒΜ, Chicago, IL, USA).\n\nThe study is anticipated to explore whether consumption of high-phenolic olive oil favorably modulates markers related to obesity and metabolic abnormalities, while also improving nutritional status and quality-of-life parameters.",[28,269,270,271],"Overweight , Obesity","Metabolic Abnormalities","Consented to Participate in the Trial and Signed an ICF",[273,274,275,276,277,278,279],"extra virgin, high-phenolic olive oil","overweight","obesity","metabolic disorders","metabolism","oxidative stress","inflammation","2026-02-26",{"date":282,"type":38},"2026-03-03",{"date":284,"type":38},"2025-03-03",{"date":286,"type":19},"2027-05",{"name":288,"class":45},"University of Peloponnese",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":82,"enrollmentInfo":296,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":74},"100559761","turkish-validity-reliability-of-the-outcome-expectations-for-yoga-scale-100559761","NCT06568341","Turkish Validity-Reliability of the Outcome Expectations For Yoga Scale","Turkish Validity and Reliability of the Outcome Expectations For Yoga Scale","Inclusion Criteria:\n\n* Adults aged 18 years and older\n\nExclusion Criteria:\n\n* Pregnant women\n* Body Mass Index above 40\n* Practiced yoga, Tai Chi, Qi Gong, or a mindfulness-based therapy program 2 times or more in the past month or 10 times in the past year",{"count":297,"type":19},200,"Evaluation of the Turkish validity and reliability of the outcome Expectations for Yoga (OEY) Scale, which was developed to evaluate attitudes and beliefs related to yoga practice",[28],[301,302,303,304],"yoga","outcome expectations","psychometric","validation","2026-02-22",{"date":307,"type":38},"2026-02-25",{"date":309,"type":38},"2024-09-01",{"date":311,"type":19},"2026-12-30",{"name":313,"class":45},"Hacettepe University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":20,"phases":321,"briefSummary":322,"conditions":323,"keywords":328,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100626374","exploring-the-feasibility-of-using-virtual-reality-as-an-educational-tool-in-chronic-pain-rehabilitation-100626374","NCT07434804","Exploring the Feasibility of Using Virtual Reality as an Educational Tool in Chronic Pain Rehabilitation","Inclusion Criteria:\n\n* ≥18 years old\n* Diagnosed with chronic pain by a consultant in pain medicine or a general practitioner with any type of chronic pain for at least 3 months\n* Report a pain intensity of \\>3 on a Numerical Rating Scale\n* Be proficient in written and spoken English\n\nExclusion Criteria:\n\n* Not able to provide informed consent\n* Scheduled for surgical treatment related to their pain condition within the next 6 months\n* Have a medical\u002Fpsychiatric condition that would prevent engagement in the pain education programme",{"count":57,"type":19},[22],"Introduction: Chronic pain significantly impacts quality of life and requires comprehensive management strategies. Traditional pain education programs are beneficial but often require significant and prolonged patient engagement. Virtual reality (VR) offers a novel approach by creating immersive environments that may enhance the effectiveness of pain education. This protocol outlines a feasibility study to investigate the use of a Virtual Reality (VR) pain education program for people living with chronic pain (PwCP).\n\nAim of the investigation: To evaluate the feasibility and acceptability of delivering a VR pain education program for PwCP. The secondary aim will explore the pre-to-post-test changes in clinical outcomes as proof of concept for a future larger scale investigation.\n\nMethods: We will use Reality Health™ as the VR tool to deliver pain science education. The study will be conducted as a single-arm feasibility study using a pretest:posttest design. Fifty PwCP will engage in the six-week Reality Health™ programme. This education programme focuses on the neurophysiology of pain, pain modulation techniques, cognitive-behavioural strategies and guided virtual exercises.\n\nResults: Primary outcome measures will include the feasibility, acceptability and safety of Reality Health™ including recruitment, retention, intervention adherence and attrition rates. Secondary outcomes will explore the pre-to-post-test changes in outcome measures relating to pain intensity, pain interference, pain self-efficacy, pain self catastrophizing, quality of life and depression as proof of concept for a future larger scale investigation.\n\nConclusions: Results will establish the feasibility, acceptability and safety of using Reality Health™ in the treatment of chronic pain, informing a future randomised control trial.\n\nEthical approval: Ethics has been granted from University College Dublin's Human Research Ethics Board (HREC-LS-25-868587).\n\nAcknowledgements: This work is funded through the Interreg north-west Europe project 'Scale-Up Rehab,'approved and funded by the European Commission \\[NWE0100082\\].\n\nDisclosures: None.\n\nKeywords: Virtual Reality, Chronic Pain, Pain Education, Feasibility Study, Protocol",[218,324,325,28,326,327],"Chronic Pain","Chronic Pain (Back \u002F Neck)","Virtual Reality","Neuroscience Pain Education",[329,330,331],"Physiotherapy","rehabilitation","Ireland","2026-02-19",{"date":334,"type":38},"2026-02-27",{"date":336,"type":19},"2026-02-20",{"date":338,"type":19},"2026-12-31",{"name":340,"class":45},"University College Dublin",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":348,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":20,"phases":350,"briefSummary":351,"conditions":352,"keywords":362,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":381},"100587890","phorte-therapy-efficacy-in-person-versus-telehealth-100587890","NCT06934265","PhoRTE® Therapy Efficacy: In-Person Versus Telehealth","Phonation Resistance Training Exercises (PhoRTE®) Delivered In-person and Via Telehealth: A Noninferiority Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults 55+ with a primary diagnosis of presbyphonia, age-related voice changes, and\u002For vocal fold atrophy with or without localized loss of lamina propria (e.g. vocal fold scar)\n* Telehealth-capable device (e.g., tablet, computer) with microphone, speaker, camera, high-speed internet\n* Ability to attend four telehealth or in-person sessions for four consecutive sessions\n* Ability to attend two in-person evaluation sessions (pre- and post-treatment)\n\nExclusion Criteria:\n\n* Presence of localized masses, lesions, or vocal fold motion impairments identified during videostroboscopy at initial evaluation\n* Progressive neurologic conditions, e.g. Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Progressive supranuclear palsy (PSP), etc.\n* Previous attendance to exuberant voice therapy (e.g., PhoRTE, Lee Silverman Voice Treatment)\n* Untreated hearing loss\n* Non-English speakers","54 Years",{"count":162,"type":19},[22],"This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors.\n\nThe two primary hypotheses are:\n\n1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face?\n2. Can online therapy be a more accessible way for older adults to get help for their voice problems?\n\nAdults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through:\n\n* Changes in voice function\n* Patient reports about their voice\n* Scientific measurements of voice quality\n* Patient satisfaction with treatment\n* Impact on quality of life\n\nThe results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.",[353,354,355,356,357,358,28,359,360,361],"Atrophy of Vocal Cord","Presbyphonia","Dysphonia","Glottic Insufficiency","Voice Change","Voice Disorder","Aging","Speech Therapy","Voice Alteration",[363,364,365,366,367,368,369,370,371],"Vocal fold atrophy","voice therapy","presbyphonia","aging voice","voice rehabilitation","speech pathology","Intervention","voice","aging","2026-01-09",{"date":374,"type":38},"2026-01-13",{"date":376,"type":19},"2026-01-25",{"date":378,"type":19},"2026-10-25",{"name":380,"class":45},"University of Southern California",4,{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":20,"phases":393,"briefSummary":394,"conditions":395,"keywords":399,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":46},"100614927","mindfulness-walking-intervention-to-enhance-resilience-iwalk-100614927","NCT07285954","Mindfulness Walking Intervention to Enhance Resilience (iWalk)","A Randomized Controlled Trial of a Walking Meditation Intervention (iWalk) to Enhance Resilience in Adults","iWalk","Inclusion Criteria:\n\n1. 18 years or older,\n2. clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc.,\n3. have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs,\n4. never received meditation training via coaching\u002Fcertification\u002Flife coaching,\n5. have internet access,\n6. with no severe cognitive impairment, i.e., have a score of ≥ 21 on Modified Telephonic Interview for Cognitive Status (TICS-M),\n7. be able to walk with or without an assistive device (Patient determined Disease Steps score ranged from 0-6),\n8. are willing to be randomized to an intervention or a control group,\n9. are willing to wear Fitbit (a wrist smart watch) for eight weeks,\n10. are individuals who are right-handed according to the Edinburgh Handedness Questionnaire,\n11. are willing to participate in all assessments, including in-person testing using electroencephalography (EEG) and cognitive tests, online survey\u002Fquestionnaires, and online interviews or focus group discussions,\n12. are willing to wear a Hexoskin t-shirt, which is a heart rate variability monitor, while doing the assessments in person.\n\nExclusion Criteria:\n\nParticipants who cannot speak, read, write, or listen in English.","110 Years",{"count":392,"type":19},90,[22],"This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS).\n\nThe objectives are to evaluate:\n\n1. Recruitment capability and retention rates,\n2. Acceptability and adherence to the intervention,\n3. Feasibility of assessment procedures, and\n4. Preliminary effects on psychological, physiological, and behavioral outcomes.",[396,397,398,28],"Neurodegenerative Disease","EEG","Mindfulness",[400,401,397],"Walking meditation","Emotional regulation","2025-12-02",{"date":404,"type":38},"2025-12-16",{"date":406,"type":38},"2025-06-01",{"date":408,"type":19},"2029-12-31",{"name":410,"class":45},"University of Illinois at Urbana-Champaign",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":16,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":20,"phases":422,"briefSummary":423,"conditions":424,"keywords":428,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":46},"100595549","adapting-implementing-and-evaluating-the-effectiveness-of-harp-for-people-with-disabilities-100595549","NCT07033897","Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities","Adapting, Implementing and Evaluating the Effectiveness of the Home Hazard Removal Program for People With Disabilities","HARP3","Inclusion Criteria:\n\n* age 45-64 years\n* self-report of difficulty with ≥2 daily activities\n* have had a physical disability for ≥5 years (e.g., spinal cord injury, cerebral palsy, post-polio syndrome, stroke, amputation)\n* live in the City of St. Louis\n* had a fall in the past year, or are worried about falling, or feel unsteady when standing or walking\n\nExclusion Criteria:\n\n• individuals who are institutionalized","45 Years","64 Years",{"count":18,"type":19},[22],"The Home Hazard Removal Program (HARP) is an effective fall prevention intervention program which targets home hazard identification\u002Fremoval. In this study the investigators will examine the effectiveness and implementation potential of HARP, adapted for PwD. Investigators will conduct a pilot randomized control trial (RCT) to test the implementation, cost, and preliminary efficacy of an adapted version of HARP for community-dwelling PwD. The single-blinded feasibility RCT will randomize 40 participants to treatment (adapted HARP) and 40 to a waitlist control group. Data on specific types of fall hazards and resulting home modifications as well as falls and fall-related injuries (collected monthly over 12 months) and fear of falling (collected at baseline and 12 months) will inform the preliminary efficacy of adapted HARP among PwD. To ensure usefulness, relevance, and broad dissemination of findings, the investigators will adopt a \"designing for implementation and dissemination\" approach. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework will guide intervention adaptation, trial design, and future implementation. The Practical Robust Implementation and Sustainability Model (PRISM) guides study development by identifying multi-level contextual factors hypothesized to affect the RE-AIM outcomes.",[425,426,427,28],"Disabilities Physical","Falls","Fall Prevention",[429,426,430,28,431,432],"Fall prevention","People with disabilities","Home Hazard Removal Program","Occupational Therapy","2025-11-13",{"date":435,"type":38},"2025-11-14",{"date":437,"type":38},"2025-08-20",{"date":439,"type":19},"2028-03-14",{"name":441,"class":45},"Washington University School of Medicine",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":20,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":4},"100609014","impact-of-probiotic-ultraflora-triplebiotic-on-weight-evolution-on-people-after-discontinuation-of-glp-1-treatment-100609014","NCT07209046","Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.","A Randomized, Double-blind, Double-arm Study Conducted Directly With Consumers Via an App \"Baritastic App\", Evaluating the Efficacy of a Supplement Containing Bifidobacterium Lactis B420 and Pasteurized Akkermansia Muciniphila (UltraFlora® Triplebiotic) for 3 Months in Adults After Discontinuation of GLP-1 Treatment.","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 \\\u003C BMI \\\u003C 30)\n4. Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year.\n5. Having stopped GLP-1 treatment for a maximum of 4 weeks\n6. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n7. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Being on GLP-1 treatment\n2. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n3. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n4. Suffering from any uncontrolled endocrine disorder.\n5. Having consumed any probiotic supplements in the 3 months prior to enrollment.\n6. Having used any antibiotic treatment in the 3 months prior to enrollment.\n7. Having a known allergy to the ingredients in the study product.\n8. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n9. Participating in an other clinical trial.\n10. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n11. Taking UltraFlora® Triplebiotic or any similar product from competitors prior to trial participation",{"count":450,"type":19},128,[22],"This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.",[28,454],"GLP-1","2025-09-29",{"date":457,"type":38},"2025-10-06",{"date":459,"type":19},"2025-11-01",{"date":151,"type":19},{"name":198,"class":199},{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":20,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100602967","impact-of-multivitamin-phytomulti-and-a-probiotic-ultraflora-balance-probiotic-on-gut-health-of-people-taking-glp-1-medication-100602967","NCT07130396","Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication","A Single Arm Trial to Evaluate the Effect of PhytoMulti® Multivitamin and UltraFlora® Balance Probiotic on Bowel Symptoms in Individuals Using GLP-1 Receptor Agonists, Assessed by the IBS Symptom Severity Score (IBS-SSS)","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Minimum 4 weeks on GLP-1 (f.e Ozempic®, Wegovy®, Mounjaro®, etc.) and maximum 1 year on GLP-1\n4. Body Mass Index (BMI) ≥ 25 AND ≤ 30\n5. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n6. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n2. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n3. Suffering from any uncontrolled endocrine disorder\n4. Having used any antibiotic treatment in the 2 months prior to enrollment.\n5. Having a known allergy to the ingredients in the study product.\n6. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n7. Participating in another clinical trial.\n8. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n9. Taking PhytoMulti® Multivitamin and\u002For UltraFlora® Probiotic or any similar product from competitors prior to trial participation",{"count":470,"type":19},100,[22],"This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.",[454,28],"2025-08-12",{"date":476,"type":38},"2025-08-19",{"date":459,"type":19},{"date":479,"type":19},"2026-04-30",{"name":198,"class":199},{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":20,"phases":490,"briefSummary":491,"conditions":492,"keywords":496,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":46},"100591696","a-feasibility-randomised-controlled-trial-of-an-online-exercise-programme-for-adults-with-cerebral-palsy-100591696","NCT06983782","A Feasibility Randomised Controlled Trial of an Online Exercise Programme for Adults With Cerebral Palsy","CP-EXCEL: A Feasibility Randomised Controlled Trial of an Online Exercise Programme for Adults With Cerebral Palsy","Inclusion Criteria:\n\n* Adults aged 18 and over with cerebral palsy (CP) residing on the island of Ireland.\n* Individuals of any Gross Motor Function Classification System (GMFCS) level.\n* Individuals with other associated impairments.\n* People with mild-to-moderate intellectual disability who can access the online platform and follow study instructions, with or without support.\n\nExclusion Criteria:\n\n* Individuals with severe intellectual disability where sufficient adaptations cannot be made.\n* Adults with unstable medical conditions.",{"count":489,"type":19},60,[22],"Adults with cerebral palsy (CP) often face challenges in accessing exercise programmes that are appropriate for their needs. Barriers such as limited mobility, a lack of tailored options, and restricted access to physiotherapy services can make participation difficult. Exercise is important for improving physical health, mental well-being, and overall quality of life. However, many adults with CP do not have regular opportunities to take part in structured physical activity. This study aims to investigate whether an online exercise programme can serve as an effective and accessible alternative.\n\nThe main aim of the study is to assess the feasibility of delivering an online exercise programme for adults with CP. Key areas of focus will include demand, implementation, practicality, adaptability, acceptability, and potential benefits to physical, mental, and social well-being.\n\nA total of 60 adults with CP will be recruited and randomly assigned to one of two groups (30 participants per group). One group will complete an 8-week online exercise and education programme. The second group will receive the same educational materials during the study and will be provided with information about the home exercise programme after the 8-week intervention period. Data will be collected on attendance, completion rates, engagement with exercises, and any reported adverse events. Health-related surveys will be completed before and after the programme to assess any changes. In addition, a selected group of participants from the intervention group will take part in interviews to provide feedback on their experiences.\n\nFindings from this study may support the development of accessible, effective, and person-centred online exercise programmes for adults with CP. Results may help improve future programme design and contribute to better care and support for adults with CP in Ireland.",[493,494,28,495],"Cerebral Palsy","Exercise","Fitness",[497,498,499],"Adults with cerebral palsy","Online exercise programme","physiotherapy","2025-07-30",{"date":502,"type":38},"2025-08-03",{"date":504,"type":38},"2025-07-25",{"date":196,"type":19},{"name":507,"class":45},"Royal College of Surgeons, Ireland",{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":20,"phases":517,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":533,"locationsCount":46},"100593351","ultra-long-peripheral-catheter-versus-accelerated-seldinger-technique-long-peripheral-catheter-in-difficult-iv-access-patients-100593351","NCT07005310","Ultra-Long Peripheral Catheter Versus Accelerated Seldinger Technique Long Peripheral Catheter in Difficult IV Access Patients","Ultra Long Peripheral Catheter Versus Accelerated Seldinger Technique Long Peripheral Catheter in Difficult Intravenous Access Patients: a Pragmatic Randomised Controlled Trial","ULAST","Inclusion Criteria:\n\n* Adult inpatients with DIVA, requiring placement of a long peripheral catheter, will be included in the study.\n* A digital request form for venous access must be completed by the treating physician at the ward.\n* Patients must be proficient in either Dutch or French\n* Patients must have decision-making capacity or be represented by a legal representative.\n\nExclusion Criteria:\n\n* Expected therapy duration of less than 24 hours\n* pregnancy\n* Need for central venous access\n* Inability to locate a deep peripheral vein in the upper extremity prior enrollment in the study\n* Veins located deeper than 1.6cm prior enrollment in the study\n* withdrawal of consent, or presentation at a time when study personnel are unavailable.",{"count":470,"type":19},[22],"The aim of this study is to perform a comparative analysis of clinical outcomes associated with the use of an ultra-long peripheral catheter using (catheter-over-the-needle technique) versus an AST-long peripheral catheter in adult patients with difficult intravenous access (DIVA) in a real-world clinical setting. Specifically, the study will assess potential benefits, including longer mean catheter dwell time and improved catheter usability, as well as potential harms, such as increased incidence of catheter-related thrombosis, infections, phlebitis, infiltration, and unplanned catheter removal.",[520,28],"Difficult Intravenous Access",[522,523,524,525,526],"Long peripheral catheter","Accelerated seldinger technique","Pragmatic randomized controlled trial","Dwell time","complications","2025-06-02",{"date":529,"type":38},"2025-06-05",{"date":531,"type":19},"2025-07-01",{"date":479,"type":19},{"name":534,"class":45},"University Ghent",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":20,"phases":544,"briefSummary":546,"conditions":547,"keywords":552,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":562,"leadSponsor":563,"locationsCount":46},"100582175","phase-4-dexmedetomidine-esketamine-combination-and-sleep-disturbances-after-major-noncardiac-surgery-100582175","NCT06859892","Dexmedetomidine-Esketamine Combination and Sleep Disturbances After Major Noncardiac Surgery","Effect of Dexmedetomidine-esketamine Combination on Sleep Disturbances After Major Noncardiac Surgery: a Single-center, Randomised, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Aged ≥18 years.\n2. Scheduled for major noncardiac surgery (≥60 minutes) under general anesthesia with an expected end of surgery no later than 18:00 pm.\n3. Required patient-controlled intravenous analgesia after surgery.\n\nExclusion Criteria:\n\n1. Emergency surgery, transurethral surgery, organ transplantation.\n2. Pregnant or lactating women.\n3. Patients who need hypnotics for sleep disturbance or antidepressants for depression prior to surgery.\n4. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis.\n5. Inability to communicate due to coma, severe dementia, or speech disorders, endured hypoxic encephalopathy or traumatic brain injury, or after neurosurgery.\n6. Comorbid with hyperthyroidism and pheochromocytoma.\n7. Preoperative left ventricular ejection fraction \\\u003C30%, sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C50 beats\u002Fmin), atrioventricular block of degree II or higher without pacemaker implantation, or systolic blood pressure below 90 mmHg despite use of vasopressors.\n8. Diagnosed as sleep apnea, or judged to be at high risk of moderate-to-severe sleep apnea as assessed by STOP-Bang.\n9. Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (on dialysis), or ASA classification ≥IV.\n10. Hypersensitive to dexmedetomidine and\u002For esketamine.\n11. Other conditions that are deemed unsuitable for study participation.",{"count":543,"type":19},476,[545],"PHASE4","Sleep disturbances are common early after major surgery, and are associated with delayed recovery. A previous study showed that dexmedetomidine-esketamine combination as a supplement to patient-controlled intravenous analgesia improved postoperative analgesia and subjective sleep quality in patients after scoliosis correction surgery. The purpose of this trial is to test the hypothesis that dexmedetomidine-esketamine combination used as a supplement during general anesthesia and postoperative intravenous analgesia may reduce sleep disturbances in adult after major noncardiac surgery.",[28,548,549,550,551],"Major Noncardiac Surgery","Dexmedetomidine","Esketamine","Postoperative Sleep Disturbances",[553,554,555,556,557],"adults","major noncardiac surgery","dexmedetomidine","esketamine","postoperative sleep disturbances","2025-03-18",{"date":560,"type":38},"2025-03-19",{"date":558,"type":38},{"date":174,"type":19},{"name":564,"class":45},"Peking University First Hospital",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":20,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":46},"100562936","digital-art-and-artificial-intelligence-100562936","NCT06609642","Digital Art and Artificial Intelligence","Digital Art and Artificial Intelligence : Encouraging the Discovery of the Senses Via the Impressionist Painters for the Well-being of Adults - Qualitative Study","1. For adults of any age:\n\n   1. Inclusion criteria:\n\n      * Concordance of sex and gender.\n      * No psychiatric or cognitive disorders.\n      * Ability to understand spoken and written French.\n      * Provide written consent to participate in the study.\n   2. Exclusion criteria:\n\n      * Non-binary.\n      * Inability to provide informed consent to participate in the study.\n      * Participation in a concurrent experimental clinical study to avoid interference with our study.\n      * Inability to understand spoken and written French.\n      * Having moderate to severe visual or auditory impairment.\n2. Young adults:\n\n   The inclusion criterion is being aged between 18 and 35 years.\n3. Older adults:\n\nThe inclusion criterion is being aged 60 years or older.",{"count":162,"type":19},[22],"The study aims at examining the impact of an immersive and interactive digital application (App) that uses impressionist artworks to promote the mental well-being of both young and older adults. The goal is to study the usability and accessibility of this App, particularly for older adults, who may have sensory impairments and lower digital literacy compared to younger adults.\n\nThe study is based on the hypothesis that the App, which allows interaction with paintings by Claude Monet and Helen McNicoll, can trigger positive emotions, thereby improving users' well-being. The App uses artificial intelligence to create extensions of the paintings and music based on the sonification of electrophysiological signals captured from plants.\n\nThe study seeks to answer four research questions:\n\n1. The usage behaviors of young and older adults with the App.\n2. The impressions and feedback from users after testing the App.\n3. The obstacles and enablers to the App's use.\n4. The expectations and needs of users for better use of the App.\n\nThe study's objectives include analyzing the usage behaviors, impressions, barriers, and needs of both young and older adults. It is a qualitative study based on non-participatory observations and semi-structured interviews with young and older participants who have used the App.\n\nThe App is based on impressionist artworks, a style known for evoking positive emotions, and aims to promote mental health by harnessing the emotional power of digital art and artificial intelligence.",[28],"2025-02-10",{"date":578,"type":38},"2025-02-12",{"date":580,"type":38},"2025-01-22",{"date":582,"type":19},"2026-02",{"name":584,"class":585},"Olivier Beauchet","OTHER_GOV",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":82,"enrollmentInfo":593,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":46},"100520282","turkish-version-of-digital-eye-strain-questionnaire-desq-100520282","NCT06054542","Turkish Version of Digital Eye Strain Questionnaire (DESQ)","Validity and Reliability of the Turkish Version of Digital Eye Strain Questionnaire (DESQ)","Inclusion Criteria:\n\n* Between the ages of 18-65 years\n* People who spend two or more continuous hours a day on their digital devices (computer, tablet, smartphone) or use more than one device\n\nExclusion Criteria:\n\n* History of ophthalmic surgery or active ocular disease\n* Participants who did not understand the instructions or did not sign a consent form were excluded",{"count":594,"type":19},130,"The aims of this study were to perform cultural adaptation of the DESQ and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking adults.",[597,598,599,28,600],"Cultural Adaptation","Reliability","Validity","Eye Strain","2024-10-11",{"date":603,"type":38},"2024-10-15",{"date":605,"type":38},"2023-10-30",{"date":607,"type":19},"2024-12",{"name":609,"class":45},"Alanya Alaaddin Keykubat University",{"id":611,"slug":612,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":618,"targetDuration":620,"studyType":58,"phases":4,"briefSummary":621,"conditions":622,"keywords":629,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":4},"100553047","algerian-cholecystectomy-outcomes-and-determinants-study-al-cods-100553047","NCT06481007","ALgerian Cholecystectomy Outcomes and Determinants Study (AL-CODS)","Algerian Cholecystectomy Outcomes and Determinants Study","AL-CODS","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Undergoing cholecystectomy.\n* Surgery performed in public or private hospitals in Algeria.\n* Surgery performed from January 1, 2025, to June 30, 2025.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients refusing to participate.\n* Cholecystectomy performed for Gallbladder cancer.\n* Cholecystectomy performed outside the inclusion period.\n* Cholecystectomies performed in conjunction with other major surgeries.",{"count":619,"type":19},500,"1 Month","Cholecystectomy, the surgical removal of the gallbladder, is a common procedure performed to treat benign gallbladder diseases such as cholelithiasis (gallstones), cholecystitis (inflammation of the gallbladder), and biliary dyskinesia. While generally considered safe, this surgery can be associated with significant morbidity and mortality, particularly in certain populations or healthcare settings. Understanding these outcomes and the factors influencing them is crucial for improving patient care and surgical practices.\n\nIn Algeria, the healthcare landscape presents unique challenges and opportunities for evaluating surgical outcomes. Limited studies have specifically focused on the morbidity and mortality associated with cholecystectomy in this context. This study aims to fill that gap by providing comprehensive data on 30-day postoperative outcomes following cholecystectomy for benign gallbladder diseases in Algeria. Such data is essential for benchmarking current practices, identifying areas for improvement, and ultimately enhancing patient safety and surgical efficacy.",[623,28,624,625,626,627,628],"Cholecystectomy","Gall Stone","Polyps","Pancreatitis Biliary","Gallbladder Dyskinesia","Cholecystitis",[630,623,631,632,633,634],"Algeria","mortality","morbidity","30 days","determinants","2024-06-26",{"date":637,"type":38},"2024-07-01",{"date":639,"type":19},"2025-01-01",{"date":641,"type":19},"2025-07-02",{"name":643,"class":45},"University of Oran 1",{"id":645,"slug":646,"hasResults":11,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":15,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":46},"100358617","effects-of-exercise-therapy-and-soft-brace-on-knee-osteoarthritis-100358617","NCT03949400","Effects of Exercise Therapy and Soft Brace on Knee Osteoarthritis","Inclusion Criteria:\n\nAssigned for exercise and education due to knee osteoarthrosis Age 18 years or older at the time of recruitment Able to read and understand Danish\n\nExclusion Criteria:\n\nNot mentally able to reply to the questionnaire",{"count":651,"type":19},40,"The primary aim of the study is to investigate the effects of supervised exercise therapy and education on the immediate response to using a soft knee brace in patients with knee osteoarthritis (OA).",[654,655,218,656,657,658,659,28,660],"Rehabilitation","Treatment Outcome","Knee Brace","Outcome Assessment (Health Care)","Recovery of Function","Patient Reported Outcome Measures","Osteoarthritis, Knee","2019-05-10",{"date":663,"type":38},"2019-05-14",{"date":665,"type":38},"2018-04-24",{"date":667,"type":19},"2029-05-20",{"name":669,"class":45},"University College of Northern Denmark"]